Nakao I, Wakui A, Hattori T, Sugimachi K, Saito T
Dept. of Internal Medicine, Cancer Institute Hospital.
Gan To Kagaku Ryoho. 1991 Jul;18(8):1325-32.
A multi-institutional collaborative phase II study of (2"R)-4-O-tetrahydropyranyladriamycin (THP) was performed by intravenous administration to patients with advanced or recurrent gastric cancer. The administration schedules were (1) 40-60 mg/body every 3 or 4 weeks and (2) 20-40 mg/body once a week. Of 58 registered patients, 49 cases were eligible and 37 cases were evaluable for response. The therapeutic results were 1 CR, 4 PR, 14 NC and 18 PD. The response rate of the evaluable cases was 13.5%. The side effects were mainly bone marrow suppression and digestive symptoms. In particular, the frequency of leukopenia was a high 75.5%, while there was a decrease in hemoglobin in 38.8% and anorexia in 30.6%. The frequency and severity of alopecia, which is a known problem with anthracyclines, were slight, and no abnormal electrocardiograms were observed.
对晚期或复发性胃癌患者进行了一项多机构合作的II期研究，通过静脉注射给予（2“R）-4-O-四氢吡喃阿霉素（THP）。给药方案为：（1）每3或4周40-60mg/体；（2）每周一次20-40mg/体。58例登记患者中，49例符合条件，37例可评估疗效。治疗结果为1例完全缓解（CR），4例部分缓解（PR），14例疾病稳定（NC），18例疾病进展（PD）。可评估病例的缓解率为13.5%。副作用主要是骨髓抑制和消化系统症状。特别是，白细胞减少的发生率高达75.5%，而血红蛋白降低的发生率为38.8%，食欲不振的发生率为30.6%。作为蒽环类药物已知问题的脱发的发生率和严重程度较轻，未观察到异常心电图。
